• In February 2026, Sanofi and Teva Pharmaceutical Industries reported that duvakitug, an investigational TL1A-targeting antibody, achieved durable 44-week clinical and endoscopic efficacy with consistent safety in ulcerative colitis and Crohn’s disease responders in the RELIEVE UCCD long-term extension study.
• A separate recent milestone saw the US FDA accept Teva’s New Drug Application for TEV-749, a once-monthly olanzapine injection for adult schizophrenia, underscoring the company’s push beyond generics into higher-value specialty therapies.
• We’ll now examine how duvakitug’s long-term inflammatory bowel disease data could influence Teva’s investment narrative around higher-margin innovative medicines.

We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva today, you need to believe its pivot toward higher-margin innovative medicines can offset a sluggish generics base and a still-heavy debt load. The duvakitug data and TEV-749 NDA acceptance both support that innovation story, but they do not change the near term reality that execution on late stage assets and continued deleveraging remain the key catalyst and the biggest risk.

The duvakitug long term ulcerative colitis and Crohn’s disease results sit alongside the FDA’s acceptance of Teva’s TEV-749 application for adult schizophrenia, both pointing to a broader specialty portfolio beyond AUSTEDO, AJOVY, and UZEDY. Together, they add to the pipeline that many analysts see as important for justifying Teva’s current premium earnings multiple and its recent share price outperformance.

However, while innovation is encouraging, investors should still weigh the risk that Teva’s concentrated pipeline and debt profile could...

Teva Pharmaceutical Industries' narrative projects $17.8 billion revenue and $1.5 billion earnings by 2028.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $37.95 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming only about 1 percent annual revenue growth to roughly US$17.3 billion and 2028 earnings of US$1.6 billion, so if duvakitug or related late stage assets slip, your view may align more with that cautious camp than with those who see the current data as reinforcing Teva’s long term reinvention story.

Explore 6 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth as much as 74% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.